Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5511-5521

  Kwon, Jung Hee ^a   Kim, Jongmin ^b   Park, Jin Young ^b   Hong, Sun Mi ^a   Park, Chang Wook ^a   Hong, Seok Joo ^b   Park, Sun Young ^b   Choi, Yoon Jung ^c   Do, In Gu ^d   Joh, Jae Won ^d   Kim, Dae Shick ^d   Choi, Kwan Yong ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b CbsBioscience Inc   (South Korea)

^c National Health Insurance Corporation   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; HIGH MOBILITY GROUP B2 PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HMGB2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 78349287390     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0825     Document Type: Article

References (37)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
5. Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001;29:395-401.
6. Pallier C, Scaffidi P, Chopineau-Proust S, et al. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell 2003;14:3414-26.
7. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007;17:72-9.
8. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
9. Pardo M, García Á, Thomas B, et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer 2006;119:1014-22.
10. Nagatani G, Nomoto M, Takano H, et al. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 2001;61:1592-7.
11. Balasubramani M, Day BW, Schoen RE, Getzenberg RH. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res 2006; 66:763-9.
12. He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 2000;97:5768-72.
13. Pasheva EA, Pashev IG, Favre A. Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain. J Biol Chem 1998;273:24730-6.
14. Huang J-C, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 1994;91:10394-8.
15. Suzuki S, Takeshita K, Asamoto M, et al. High mobility group box associated with cell proliferation appears to play an important role in hepatocellular carcinogenesis in rats and humans. Toxicology 2009;255:160-70.
16. Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
17. Kim J, Hong SJ, Park JH, et al. Real-time reverse transcription PCR analysis for validation of transketolase gene in hepatocellular carcinoma tissues. Biochip J 2009;3:130-8.
18. Kim J, Hong SJ, Lim EK, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20.
19. Vandesompele J, Preter KD, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3: RESEARCH0034.
20. Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 2008;98:845-51.
21. Kim D-G, Park S-Y, Kim H, Chun Y-H, Moon W-S, Park S-H. A comprehensive karyotypic analysis on a newly established sarcomatoid hepatocellular carcinoma cell line SH-J1 by comparative genomic hybridization and chromosome painting. Cancer Genet Cytogenet 2002;132:120-4.
22. Lee D, Kwon J-H, Kim EH, Kim E-S, Choi KY. HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus- postive HeLa cells. Cancer Lett 2010;292: 125-32.
23. Yamazaki F, Nagatsuka Y, Shirakawa H, Yoshida M. Repression of cell cycle progression by antisense HMG2 RNA. Biochem Biophys Res Commun 1995;210:1045-51.
24. Mitkova E, Ugrinova I, Pashev IG, Pasheva EA. The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain. Biochemistry 2005;44: 5893-8.
25. Zong W-X, Ditsworth D, Bauer DE, Wang Z-Q, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272-82.
26. Arioka H, Nishio K, Ishida T, et al. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. Cancer Sci 1999;90:108-15.
27. Štros M, Ozaki T, Baèíková A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-64.
28. Völp K, Brezniceanu M-L, Bösser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
29. Ellerman JE, Brown CK, Vera Md, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-48.
30. Cheng B-Q, Jia C-Q, Liu C-T, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008;40:446-52.
31. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152: 1197-206.
32. Fages C, Nolo R, Huttunen HJ, Eskelinen E-L, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000;113: 611-20.
33. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010;337:251-8.
34. Pusterla T, Marchis Fd, Palumbo R, Bianchi ME. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 2009; 42:308-10.
35. Boonyaratanakornkit V, Melvin V, Prendergast P, et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998;18: 4471-87.
36. Le X-F, Lammayot A, Gold D, et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005;280:2092-104.
37. Taniguchi N, Caramés B, Kawakami Y, Amendt BA, Komiya S, Lotz M. Chromatin protein HMGB2 regulates articular cartilage surface maintenance via β-catenin pathway. Proc Natl Acad Sci U S A 2009;106:16817-22.